KKR to Sell Minority Stake in Nordic Bioscience to Founder Claus Christiansen
核心洞察
KKR (搜索) has agreed to sell its 10% minority stake in Nordic Bioscience (搜索) to founder and majority shareholder Claus Christiansen (搜索), announced on 3 September 2026 in Copenhagen.
KKR (搜索) invested in the biomarker company in 2021 through its Health Care Strategic Growth strategy, supporting expansion across R&D services, clinical diagnostics and drug development.
During the partnership, Nordic Bioscience (搜索) doubled revenue and became more profitable while strengthening its position in extracellular matrix biomarker development.
Nordic Bioscience (搜索), a global leader in biomarker development, and KKR (搜索), a leading global investment firm, announced on 3 September 2026 in Copenhagen that KKR has entered into an agreement to sell its 10% minority stake in Nordic Bioscience to the company's founder and majority shareholder, Claus Christiansen (搜索).
KKR (搜索) invested in Nordic Bioscience (搜索) in 2021 through its Health Care Strategic Growth strategy, supporting the company as it continued to expand its biomarker capabilities and strengthen its position across R&D services, clinical diagnostics and drug development.
Strategic Partnership and Value Creation
Kugan Sathiyanandarajah, Partner and Head of KKR (搜索)'s European Healthcare Private Equity and Healthcare Strategic Growth teams, said: "We have been proud to collaborate with Claus, Morten and the Nordic Bioscience (搜索) team over the past five years. During that time, the company further strengthened its position as a leading biomarker business, building on its differentiated expertise in the extracellular matrix and expanding its capabilities across R&D services, clinical diagnostics and drug development. We are pleased with the value created during our strategic partnership and believe Nordic Bioscience is well positioned for its next phase of growth."
Claus Christiansen (搜索), Founder and majority shareholder of Nordic Bioscience (搜索), said: "KKR (搜索) has been a valued strategic partner to Nordic Bioscience, and we are grateful for their support and expertise they have brought to the company since 2021. Over this period, we have doubled revenue and become even more profitable, while continuing to strengthen our position in biomarker development."
Leadership and Governance Changes
In connection with the transaction, Chair Håkan Björklund has decided to step down from the board, and Claus Christiansen (搜索) will assume the role as Chair. Kugan Sathiyanandarajah will remain on the Board of Directors of Nordic Bioscience (搜索) until the next ordinary general meeting.
Christiansen added: "I would also like to thank Håkan for his leadership as Chair and his valuable contributions to our strategic direction and continued growth journey. Nordic Bioscience (搜索)'s business model, built around three complementary business areas that all leverage our unique expertise in the extracellular matrix, provides a strong foundation for continued growth and long-term value creation."
Nordic Bioscience's Extracellular Matrix Expertise
With more than 25 years of research and over 850 published scientific papers, Nordic Bioscience (搜索) is a pioneer in the field of extracellular matrix (ECM). The company focuses on using its unique ECM expertise to discover and develop biomarkers for use in R&D services, clinical diagnostics and drug development. Nordic Bioscience holds a broad patented ECM portfolio of over 150 biomarkers covering major disease areas such as liver, cancer and obesity.